Journal of Chemotherapy

Papers
(The TQCC of Journal of Chemotherapy is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis84
Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam63
Innovative sequential therapy in a rare case of refractory Erdheim-Chester disease with bilateral pulmonary involvement35
Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer30
Cytofluorimetric study of cerebrospinal fluid at staging of diffuse large B cell lymphoma22
Comparative in vitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis21
YAP/TAZ axis was involved in the effects of metformin on breast cancer18
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients15
Nivolumab-induced Lambert-Eaton myasthenic syndrome: an immune-related adverse event in nonsmall cell lung cancer14
Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem12
Comparative effectiveness of chemotherapy in different histological types of pancreatic cancer: a PSM-based study using the SEER database11
Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae11
MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA210
The pharmacokinetics of ganciclovir during prolonged intermittent kidney replacement therapy in a cardiac transplant recipient9
Causative agents of bloodstream infections in two Croatian hospitals and their resistance mechanisms9
Risk of peripheral edema in cancer patients receiving MET inhibitors: a systematic review and meta-analysis9
Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin9
Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals9
Identification of chemoresistance targets in doxorubicin-resistant lung adenocarcinoma cells using LC-MS/MS-based proteomics9
Reevaluating immunotherapy’s potential in first-line metastatic urothelial carcinoma9
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma8
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma8
Developing new drugs for adult T-cell leukemia/lymphoma by targeting hypoxia: insights from toxicity of MS-275 and its analogs8
Reversible chemoresistance of pancreatic cancer grown as spheroids8
Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation8
The relationship between statin administration timing and survival outcomes in patients with cancer receiving immune checkpoint blockade8
A cost minimisation analysis comparing oral linezolid and intravenous daptomycin administered via an outpatient parenteral antibiotic therapy programme in patients requiring prolonged antibiotic cours8
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer8
The role of maintenance therapy in the treatment of advanced urothelial cancer: a comprehensive systematic review and network meta-analysis7
Exploring the role of quercetin on doxorubicin and lapatinib-mediated cellular and mitochondrial responses using in vitro and in s7
Recent advances in polymer-based nanoparticles: current strategies and translational challenges in cancer therapy7
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer7
In vitro killing of multidrug/extensively drug-resistant Pseudomonas aeruginosa by fosfomycin alone or in combination with antipseudomonal antibiotics7
Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer7
Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer7
Initial cumulative area under the blood concentration-time curve of vancomycin is associated with the incidence of acute kidney injury6
Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells6
Oritavancin as sequential therapy for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis: a case report6
Examining cardiac toxicity in HER2-positive breast cancer patients using trastuzumab and its influencing factors at Iran Hospital6
Advances in MUC1 resistance to chemotherapy in pancreatic cancer6
Impact of clinical pharmacist’s interventions on clinical outcomes in appropriate use of colistin: a prospective pre-post intervention study6
Short-term neurotoxicity trajectory in patients with thoracic cancers receiving triweekly albumin-bound paclitaxel5
LncRNA POU6F2-AS2 contributes to malignant phenotypes and paclitaxel resistance by promoting SKP2 expression in stomach adenocarcinoma5
Combination therapy does not decrease 30-day mortality but increases antibiotic consumption in methicillin-sensitive S. aureus bacteraemia5
E2F1-induced transcriptional activation of MAL2 inhibits sunitinib sensitivity and promotes the malignant progression of bladder cancer5
The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study5
Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia5
Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review5
Novel SNX25-ROS1 fusion mutation confers therapeutic sensitivity to entrectinib: a case report and literature review5
METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells5
Comparison of Syrian generic ceftriaxone sodium preparations for injection: BHT content and its implications5
Emerging role of competing endogenous RNA in lung cancer drug resistance5
Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous no5
A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer5
A case of ICIs-associated arthritis caused by Toripalimab initially presenting as oedema in both lower limbs5
Antimicrobial dosing recommendations during continuous renal replacement therapy: different databases, different doses5
Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza4
Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma4
Successful treatment with oxaliplatin and programmed cell death protein 1 inhibitor in recurrent advanced endometrial carcinoma with mismatch repair defects: a case report and literature review4
Evaluation of in vitro activity of ceftaroline, ceftobiprole and their combination with trimethoprim/sulfamethoxazole against MRSA isolates: a two center study4
Anti-programmed death ligand 1 immunotherapy in patients with limited-stage small cell lung cancer: a real-world exploratory study4
Impact of a hospital sepsis management protocol on the selection of empirical antibiotics in infectious disease consultations4
Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin4
Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: a systematic review study4
Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review4
Biliary disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database4
Case report: hypertrophic osteoarthropathy improves with immune checkpoint inhibitor therapy4
Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine4
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes4
The tumor microenvironment: shaping cancer progression and treatment response4
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey4
In vitro activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing Klebsiella pneumoniae<4
Thrice-weekly teicoplanin: an old drug for modern needs. Experience of its use as outpatient parenteral antibiotic therapy (OPAT) at infectious disease unit of Manzoni hospital (Lecco)4
Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report4
Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis4
Clinical value of circulating tumour cells in evaluating the efficacy of continuous hepatic arterial infusion among colorectal cancer patients3
Resveratrol suppresses NSCLC cell growth, invasion and migration by mediating Wnt/β-catenin pathway via downregulating SIX4 and SPHK23
STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy3
Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer3
NCAPG2 promotes the proliferation, metastasis and resistance to nab-paclitaxel in gastric adenocarcinoma cells3
Global status of phenotypic pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates: an updated systematic review and meta-analysis3
Implementation of effective strategies to prevent Candida auris transmission in a Quaternary Care Center, Riyadh, Saudi Arabia3
Varicella zoster virus reactivation reported with isatuximab use3
Time to reconsider moxifloxacin anti-anaerobic activity?3
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge3
Colistin resistance among the Gram-negative nosocomial pathogens in India: a systematic review and meta-analysis3
Circ_0030411 aggravates cisplatin-resistance in non-small cell lung cancer by serving as a miR-495-3p sponge to enhance CCND1 expression3
CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner3
Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors3
Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review3
Clinical features, treatments, and outcomes of atezolizumab-induced diabetes mellitus in cancer patients3
Antihyperlipidemic drug rosuvastatin suppressed tumor progression and potentiated chemosensitivity by downregulating CCNA2 in lung adenocarcinoma3
Prognostic and immunological values of SKA3 for overall survival in lung adenocarcinoma and its RNA binding protein involved mechanisms3
Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains3
A comparative study of ceftazidime/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant Klebsiella pneumoniae 3
LncRNA-IQCH-AS1 sensitizes thyroid cancer cells to doxorubicin via modulating the miR-196a-5p/PPP2R1B signalling pathway3
Cefiderocol for Stenotrophomonas maltophilia infections: real-world evidence from a multicenter study and a comprehensive literature review3
0.15720009803772